Eli Lilly and Company (NEO:ZLLY)
Canada · Delayed Price · Currency is CAD | Market Cap | 1.54T +60.6% |
| Revenue (ttm) | 100.85B +47.4% |
| Net Income | 35.28B +127.6% |
| EPS | 39.30 +129.1% |
| Shares Out | n/a |
| PE Ratio | 43.57 |
| Forward PE | 32.88 |
| Dividend | 0.05 (0.40%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 150 |
| Open | 12.96 |
| Previous Close | 13.05 |
| Day's Range | 12.92 - 12.96 |
| 52-Week Range | 9.09 - 13.05 |
| Beta | 0.51 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Eli Lilly price target raised to $1,334 from $1,251 at BofA
BofA raised the firm’s price target on Eli Lilly (LLY) to $1,334 from $1,251 and keeps a Buy rating on the shares. Second quarter results are expected to highlight stronger…
Eli Lilly price target raised to $1,370 from $1,281 at Truist
Truist raised the firm’s price target on Eli Lilly (LLY) to $1,370 from $1,281 and keeps a Buy rating on the shares ahead of its Q2 results. The quarter could…
Eli Lilly to presents abstracts at 2026 AAIC on Kisunla trials
Eli Lilly (LLY) announced it will present 16 abstracts at the 2026 Alzheimer’s Association International Conference, AAIC,, July 12-15 in London. Three oral presentations anchor the scientific program...
Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
Analyses across Kisunla (donanemab-azbt) trials providing further insights into the benefit-risk profile from long-term extension data New data compares the diagnostic performance of P-tau217 blood te...
Eli Lilly Stock (LLY) Gets a Boost as Eczema Treatment Receives a Positive Recommendation in Canada
There is more to the company than weight-loss drugs.
Strong LLY News Boosts Active Healthcare ETF GDOC
Healthcare and technology provide an intriguing contrast. Many healthcare stocks are traditionally known for their more defensive uses in portfolios.
Eli Lilly Stock (LLY) Gets a Boost as Eczema Treatment Receives a Positive Recommendation in Canada
There is more to the company than weight-loss drugs.
Eli Lilly price target raised to $1,500 from $1,250 at RBC Capital
RBC Capital raised the firm’s price target on Eli Lilly (LLY) to $1,500 from $1,250 and keeps an Outperform rating on the shares in a preview of its Q2 results.
Eli Lilly price target raised to $1,347 from $1,344 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Eli Lilly (LLY) to $1,347 from $1,344 and keeps an Overweight rating on the shares. Biotech could benefit from…
Health Canada approves Eli Lilly’s Mounjaro for use in children 10 years old
Eli Lilly (LLY) Canada announced that Mounjaro is now indicated as an adjunct to diet and exercise to improve glycemic control in pediatric patients living with type 2 diabetes aged…
Eli Lilly price target raised to $1,400 from $1,300 at JPMorgan
JPMorgan raised the firm’s price target on Eli Lilly (LLY) to $1,400 from $1,300 and keeps an Overweight rating on the shares. The firm sees potential upside for Mounjaro from…
Eli Lilly price target raised to $1,350 from $1,230 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Eli Lilly (LLY) to $1,350 from $1,230 and keeps an Overweight rating on the shares. Large-cap biopharmas are expected to report broadly…
AI Is the Ultimate Growth Tailwind for Eli Lilly (LLY). Here’s Why
Artificial intelligence (AI) could prove to be a huge long-term growth tailwind for Eli Lilly ($LLY), as it’s transforming the company’s multi-decade trajectory. AI is changing how the company discove...
Several Analysts Pounds the Table on Eli Lilly Stock (LLY) Heading into Earnings
The company has several catalysts to drive its share price higher.
Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results
Eli Lilly and Company (LLY) shares up 18,585% since Big Money bought big in 1990.
Eli Lilly Stock (LLY) Retreats as China Threats Emerge
The shares recently hit an all-time high.
Innovent Biologics, Eli Lilly enters Verzen distribution and promotion agreement
Innovent Biologics (IVBXF) and Eli Lilly (LLY) jointly announced that they have entered into a distribution and promotion agreement regarding Lilly’s CDK4 & 6 inhibitor Verzenios in mainland China. In...
Medicare will start covering obesity drugs for the first time. Here's what patients should know
Starting Wednesday, eligible seniors with Medicare coverage can access GLP-1s for obesity with a copay of just $50 per month through a temporary program called Bridge. The move could unlock a vast new...
China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug
Innovent Biologics has entered into an agreement that grants it sole commercialization rights for Eli Lilly's breast cancer drug Verzenios in mainland China, the Chinese drugmaker said Tues...
Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commerciali...
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
The U.S. Food and Drug Administration has selected Eli Lilly and Regeneron , among seven companies, for a pilot program to accelerate reviews of new domestic pharmaceutical manufacturing fa...
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
Eli Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA's PreCheck pilot program. The FDA PreCheck...
GAME CHANGER: Eli Lilly launches $50 Medicare GLP-1 program
Eli Lilly CEO Dave Ricks joins 'Varney & Co.' to discuss the Trump administration's new Medicare GLP-1 Bridge Program, which will offer eligible seniors access to Lilly weight loss medications for $50...
Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet
Millions of older Americans in Medicare are about to gain access to obesity drugs through Medicare's new Bridge demonstration program for a monthly copay of just $50. But many seniors may be unaware o...
